1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II studyKyung-Woo Lee, Y-K. Kang, Y-H Im et al.|Annals of Oncology|2023Cited by 8
132MO Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the phase IIb HERIZON-BTC-01 studyHsin‐Yun Sun, D-Y. Oh, Jae‐Weon Kim et al.|Annals of Oncology|2023Cited by 0